We have located links that may give you full text access.
JOURNAL ARTICLE
OBSERVATIONAL STUDY
Tolerance to Induced Astigmatism With a Monofocal Intraocular Lens Designed to Extend the Depth of Focus.
Journal of Refractive Surgery 2023 April
PURPOSE: To determine tolerance to residual astigmatism and visual performance in eyes implanted with a monofocal intraocular lens (IOL) designed to extend the depth of focus (Tecnis Eyhance, DIB00; Johnson & Johnson Vision) compared to eyes implanted with a standard monofocal IOL (Tecnis ZCB00; Johnson & Johnson Vision).
METHODS: This prospective, observational study enrolled consecutive patients who underwent routine cataract surgery and implantation of either the DIB00 (n = 20) or ZCB00 (n = 20) IOL. Astigmatic defocus was induced with a plus cylinder from +0.50 to +2.00 diopters (D) in 0.50-D steps for each astigmatic orientation (against-the-rule [ATR], with-the-rule [WTR], and oblique). Outcome measures included the comparison of mean visual acuity at each step of defocus, astigmatic defocus curves, and near and intermediate visual acuity.
RESULTS: Eyes implanted with the DIB00 demonstrated greater astigmatic tolerance and were more likely to maintain 20/40 or better visual acuity with up to +2.00 D of induced ATR and oblique astigmatism than the ZCB00 IOLs. The DIB00 group showed 1.3 lines better visual acuity at 2.00 D of ATR astigmatic defocus and 1 line better than the ZCB00 group at 1.50 D of oblique astigmatic defocus. Although the distance visual acuity was comparable, near and intermediate visual acuities (both distance-corrected and uncorrected) were better for the DIB00 IOL than for the standard ZCB00 IOL.
CONCLUSIONS: The monofocal IOL designed to extend the depth of focus (DIB00 group) showed greater tolerance to induced astigmatism in ATR and oblique orientations and superior uncorrected and distance-corrected near and intermediate visual acuity than the standard monofocal IOL of the same IOL platform. [ J Refract Surg . 2023;39(4):222-228.] .
METHODS: This prospective, observational study enrolled consecutive patients who underwent routine cataract surgery and implantation of either the DIB00 (n = 20) or ZCB00 (n = 20) IOL. Astigmatic defocus was induced with a plus cylinder from +0.50 to +2.00 diopters (D) in 0.50-D steps for each astigmatic orientation (against-the-rule [ATR], with-the-rule [WTR], and oblique). Outcome measures included the comparison of mean visual acuity at each step of defocus, astigmatic defocus curves, and near and intermediate visual acuity.
RESULTS: Eyes implanted with the DIB00 demonstrated greater astigmatic tolerance and were more likely to maintain 20/40 or better visual acuity with up to +2.00 D of induced ATR and oblique astigmatism than the ZCB00 IOLs. The DIB00 group showed 1.3 lines better visual acuity at 2.00 D of ATR astigmatic defocus and 1 line better than the ZCB00 group at 1.50 D of oblique astigmatic defocus. Although the distance visual acuity was comparable, near and intermediate visual acuities (both distance-corrected and uncorrected) were better for the DIB00 IOL than for the standard ZCB00 IOL.
CONCLUSIONS: The monofocal IOL designed to extend the depth of focus (DIB00 group) showed greater tolerance to induced astigmatism in ATR and oblique orientations and superior uncorrected and distance-corrected near and intermediate visual acuity than the standard monofocal IOL of the same IOL platform. [ J Refract Surg . 2023;39(4):222-228.] .
Full text links
Trending Papers
Restrictive fluid resuscitation in septic shock patients has lower mortality and organ dysfunction rates than standard therapy.Shock 2023 November 11
Cardiovascular Disease in Diabetes and Chronic Kidney Disease.Journal of Clinical Medicine 2023 November 9
Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium-Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction.Diabetes Care 2023 November 22
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app